February 11, 2008
For Safety, NHLBI Changes Intensive Blood Sugar Treatment Strategy in Clinical Trial of Diabetes and Cardiovascular Disease
The National Heart, Lung, and Blood Institute (NHLBI) of the National
Institutes of Health has stopped one treatment within a large,
ongoing North American clinical trial of diabetes and cardiovascular
disease 18 months early due to safety concerns after review of
available data, although the study will continue.
